Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Social Media Guidance Gives Drug Firms A Pass On User Content

This article was originally published in The Tan Sheet

Executive Summary

The draft guidance outlines substantial reporting requirements for websites that firms control and for content on third-party sites – as well as saying when FDA intends to use enforcement discretion.

You may also be interested in...



Mucinex, Zyrtec Online Strategies Score While Most OTC Brands Miss

RB's Mucinex brand ranks highest among OTC drug brands evaluated in digital research firm L2’s Digital IQ Index, which found the OTC sector ranked last in digital ad spend among the top 10 industries. OTC product brands tend to be unsophisticated online and do not adequately link products to points of purchase.

Mucinex, Zyrtec Online Strategies Score While Most OTC Brands Miss

RB's Mucinex brand ranks highest among OTC drug brands evaluated in digital research firm L2’s Digital IQ Index, which found the OTC sector ranked last in digital ad spend among the top 10 industries. OTC product brands tend to be unsophisticated online and do not adequately link products to points of purchase.

To Improve Adverse Event Tracking, FDA Could Google It

Teleconference between Google and FDA signals the internet search giant could have a way to improve adverse-event detection. The agency calls the talk “a high-level, general discussion” of Google’s capabilities.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel